The average one-year price target for Treace Medical Concepts (NasdaqGS:TMCI) has been revised to $4.08 / share. This is an ...

Treace Medical Concepts, Inc. announced that it will release its financial results for the fourth quarter and full year of 2024 on February 27, 2025, after market close. A conference call with company ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Analysts have shifted their price targets on Treace ...

New portfolio addition taps into incremental procedures throughout the foot and ankle; strengthens Treace’s comprehensive ...

Detailed price information for Treace Medical Concepts Inc (TMCI-Q) from The Globe and Mail including charting and trades.

PONTE VEDRA, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...

PONTE VEDRA, Fla., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts (TMCI), Inc. , a medical technology company driving a fundamental shift in the surgical treatment of bunions and related ...

NEW YORK, May 16, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Treace Medical Concepts, Inc. ("Treace" or the "Company") ...

Preliminary revenue of $68.4 million to $68.8 million in the fourth quarter of 2024, an approximate 10% increase at the midpoint over the same period in 2023. Preliminary revenue of $209.0 million to ...

Successful completion of first cases utilizing the SpeedPlate™ MicroQuad™ implants, indicating progress in product development. The MicroQuad™ implant enhances the existing SpeedPlate™ platform, which ...

Image source: The Motley Fool. Treace Medical Concepts (NASDAQ:TMCI) reported decelerating growth driven by a shift in product sales mix and softness in its core lapoplasty business, citing reduced ...